<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291602</url>
  </required_header>
  <id_info>
    <org_study_id>D4280C00010</org_study_id>
    <nct_id>NCT01291602</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single and multiple dose study in healthy male and female (of non-childbearing
      potential) Japanese volunteers, to assess the safety, tolerability, and blood and urine drug
      levels of intravenous (IV) NXL104 alone and when given in combination with ceftazidime.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events will be monitored as a measure of safety and tolerability</measure>
    <time_frame>A range of 12 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs, physical examinations, clinical laboratory tests, 12 lead electrocardiogram (ECG) and digital ECG will be assessed as a measure of safety and tolerability</measure>
    <time_frame>A range of 12 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetic parameters of plasma of NXL104 alone or in combination with ceftazidime</measure>
    <time_frame>Range of 8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetic parameters of urine of NXL104 alone or in combination with ceftazidime</measure>
    <time_frame>Range of 8 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of intestinal bacterial flora of NXL104 alone or in combination with ceftazidime</measure>
    <time_frame>Range of 12 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy Male and Female Japanese Volunteers</condition>
  <arm_group>
    <arm_group_label>NXL104</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six Japanese subjects to receive single and repeated 500 mg IV infusions of NXL104</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three Japanese subjects to receive placebo IV doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ceftazidime NXL104 (CAZ104)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six Japanese subjects to receive single and repeated IV infusions of 500 mg NXL104 with 2000 mg ceftazidime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NXL104</intervention_name>
    <description>IV Solution</description>
    <arm_group_label>NXL104</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAZ104</intervention_name>
    <description>IV Solution</description>
    <arm_group_label>Ceftazidime NXL104 (CAZ104)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be considered as 'Japanese', both of the volunteer's parents, and all grandparents
             must be Japanese. The volunteer must have been born in Japan, have a valid Japanese
             passport and must not have lived outside Japan for more than 5 years

          -  Have a body mass index (BMI) between 17 and 27 kg/m2 inclusive and weigh at least 45
             kg and no more than 100 kg.

          -  Females must not be lactating, and must be of non-childbearing potential
             (post-menopausal at least 12 months or documented irreversible surgical sterilization
             by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal
             ligation

        Exclusion Criteria:

          -  History or presence of gastrointestinal, liver or kidney disease, or other conditions
             known to interfere with the absorption, distribution, metabolism, or excretion of
             drugs

          -  Symptoms of a clinically significant illness in the 3 months before the study

          -  History of hypersensitivity (eg, anaphylaxis), serious allergy, or any serious
             reaction to carbapenem, cephalosporins, or other Î²-lactam antibiotics

          -  Use within 14 days prior to the first study dose of any over-the-counter (including
             St. John's Wort or any herbal products) or prescription medication

          -  Smoker of more than 5 cigarettes/day or equivalent use of nicotine products during the
             previous 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Newell, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Yen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL Early Phase/California Clinical Trials Medical Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1456&amp;filename=D4280C00010_Study_Synopsis.pdf</url>
    <description>Study Synopsis</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2011</study_first_submitted>
  <study_first_submitted_qc>February 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2011</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NXL104</keyword>
  <keyword>ceftazidime</keyword>
  <keyword>CAZ104</keyword>
  <keyword>Healthy Japanese volunteers</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Single and Multiple Dose Study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Avibactam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

